Clincosm LogoSign in Get a demo

RYR: RhabdomYolyse in Intensive caRe

Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT06101680
Collaborator
(none)
200
Enrollment
1
Location
3
Anticipated Duration (Months)
66.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Analysis of the outcome of patients < 18 years old, treated in an intensive care unit for severe rhabdomyolysis, regardless of etiology (renal failure rate, death rate, organ replacement rate)

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    200 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    RhabdomYolyse in Intensive caRe
    Actual Study Start Date :
    Oct 1, 2023
    Anticipated Primary Completion Date :
    Dec 1, 2023
    Anticipated Study Completion Date :
    Jan 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Children in intensive care with rhabdomyosis

    Outcome Measures

    Primary Outcome Measures

    1. Use of renal remplacement therapy [7 days after admission in intensive care unit]

      Use of renal remplacement therapy in case of severe rhabdomyolysis in children in intensive care unit

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    0 Years to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • CPK > 5000 UI/L

    • Care in Pediatric Intensive Care Unit

    • Age < 18 years old

    Exclusion Criteria:
    • Parental refusal

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Reanimation Pediatrique Nancy France 54000

    Sponsors and Collaborators

    • Central Hospital, Nancy, France

    Investigators

    • Principal Investigator: Arnaud Wiedemann, MD PhD, CHRU Nancy

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Arnaud WIEDEMANN-FODE, Clinical Professor, Central Hospital, Nancy, France
    ClinicalTrials.gov Identifier:
    NCT06101680
    Other Study ID Numbers:
    • 2022PI201
    First Posted:
    Oct 26, 2023
    Last Update Posted:
    Oct 26, 2023
    Last Verified:
    Oct 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Arnaud WIEDEMANN-FODE, Clinical Professor, Central Hospital, Nancy, France
    rhabdomyolysis
    child
    Intensive Care
    Additional relevant MeSH terms:
    Rhabdomyolysis

    Study Results

    No Results Posted as of Oct 26, 2023